HHS Launches Psychiatric Drug Policy Shift: Informed Consent, Deprescr – Good Machine

TL;DR

HHS Secretary RFK Jr. has announced a federal plan emphasizing informed consent and safe deprescribing for psychiatric medications, including antidepressants.
The American Psychiatric Association supports better training for safe prescribing and weaning but calls the administration's broader framing an "oversimplification" of a complex crisis driven by insufficient access to care.
35 veterans organisations are pushing Congress to pass the Written Informed Consent Act, requiring VA providers to obtain written informed consent before prescribing psychiatric medications.
The UK's MHRA strengthened warnings on May 11, 2026 for finasteride and dutasteride, adding depression, suicidal ideation, and sexual dysfunction to product labels — a signal of transatlantic regulatory scrutiny.
No new federal rules have been finalized. The Washington Post reports the FDA under Commissioner Makary has a pattern of media announcements ahead of formal rulemaking.

The Conversation That Explains the Story

RFK Jr., HHS Secretary, May 2026: "Too many patients begin treatment without a clear understanding of the risks and how long they will stay on these drugs or how to come off of them. And they said that their providers had either discouraged them from getting off of the drugs or did not guide them on how to wean safely."

Dr. Theresa Miskimen Rivera, President, American Psychiatric Association: "It really is an oversimplification. We support any plans to better train healthcare providers to safely prescribe and wean patients off antidepressants. But the mental health crisis we are facing is not primarily a problem of over-medicalization and overprescribing. It is a problem of access."

This exchange, reported by NPR and Iowa Public Radio on May 7, 2026, is the core tension. The federal government is pivoting toward a deprescribing and informed-consent framework for psychiatric medications. The largest professional body in American psychiatry agrees with the goal — safer prescribing and safer tapering — but rejects the diagnosis that overmedicalization is the root cause.

What Happened

On May 5, 2026, NBC News Nightly News reported that "RFK Jr. launches plan to limit antidepressant prescriptions." The administration's initiative, confirmed by NPR transcripts and CBS News interviews, centres on three operational themes:

Informed consent at initiation. Patients must receive clear written information about risks, benefits, expected duration, and discontinuation protocols before starting psychiatric medications.
Shared decision-making during treatment. Providers are expected to regularly review whether continued pharmacotherapy is necessary, particularly for patients on maintenance regimens for years.
Safe tapering and deprescribing. The administration is framing abrupt discontinuation — and provider unwillingness to guide tapering — as a patient-safety failure.

Parallel developments in the same week:

Veterans' groups. On May 6, Newsweek reported that 35 organisations including the American Legion, Disabled American Veterans, and Iraq and Afghanistan Veterans of America sent a letter to Congress urging passage of the Written Informed Consent Act. The bill would require VA providers to follow the same informed-consent protocols used for opioid painkillers before prescribing psychiatric medications for mood disorders.
UK regulatory action. On May 11, the Pharmaceutical Journal reported that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) strengthened product warnings for finasteride and dutasteride. The updated labels now explicitly list depression, suicidal ideation, and sexual dysfunction — including effects that may persist after treatment stops.
SAMHSA harm-reduction reversal. On May 12, The Guardian reported that the Substance Abuse and Mental Health Services Administration (SAMHSA) issued an open letter in April ordering an end to federal fund usage for all substance testing strips, including fentanyl and xylazine. Maia Szalavitz, author of Undoing Drugs, warned: "It's going to kill people."

What It Actually Means

This is a policy signal with real operational consequences, even in the absence of finalized rules.

For prescribers and health systems: The direction of travel is clear. Documented informed consent, tapering protocols, and periodic medication reviews are becoming the expected standard of care — not the exception. CMS, which controls Medicare and Medicaid reimbursement, has enormous leverage to enforce this through quality metrics and prior-authorisation requirements even without new legislation.

For patients: The initiative addresses a genuine gap. Studies across multiple countries have found that patients initiating antidepressants often receive no written information about withdrawal syndromes, discontinuation timelines, or the evidence base for long-term maintenance. The FDA itself has never required a standardised patient handout for SSRIs comparable to the Medication Guides used for isotretinoin or opioids.

For the medical profession: The APA's calibrated response is instructive. Dr. Rivera and the association support the operational goals (better training, informed consent, safe tapering) while contesting the causal narrative. The data on antidepressant prescribing rates is genuinely mixed: U. S. prescribing has risen steadily since 2000, but the increase correlates with expanded diagnostic criteria, direct-to-consumer advertising, and — in the view of many psychiatrists — a legitimate recognition of untreated depression in primary care.

The Washington Post context: On May 7, the Post reported that RFK Jr. and FDA Commissioner Makary have repeatedly announced major health policy changes before formal rules are drafted. The food dye "phase out" announcement in March 2026, for example, turned out to be a voluntary industry agreement with no enforcement timeline. This pattern matters for the psychiatric drug initiative: the announcements may run ahead of the infrastructure required to implement them safely.

And Here's What This Isn't

A ban on psychiatric medications. No federal prohibition or class-wide restriction has been proposed.
A new law. The Written Informed Consent Act is pending in Congress. HHS initiatives announced in May 2026 have not yet produced enforceable CMS rules.
A consensus medical position. The APA, the National Alliance on Mental Illness (NAMI), and multiple academic psychiatry departments have publicly pushed back on the overmedicalization framing.
A surprise. The deprescribing movement — including the NIH-funded US Deprescribing Research Network and the international ERBP guidelines — has been building for over a decade.

Stakeholder Landscape

Who benefits from this being in the news:

Patient autonomy advocates and deprescribing researchers gain federal validation for a long-advocated framework.
Non-pharmacological mental health providers (therapists, psychedelic-assisted therapy clinics, wellness platforms) may see increased demand if medication-first treatment becomes less frictionless.
CCHR International (Citizens Commission on Human Rights, a Scientology-founded anti-psychiatry organisation) issued a press release on May 12 applauding the HHS initiative. CCHR's involvement in amplifying the story does not invalidate the policy, but it signals which ideological coalition is most energised by the framing.

Who loses:

Pharmaceutical companies with high-volume psychiatric portfolios (SSRIs, SNRIs, atypical antipsychotics, mood stabilisers) face regulatory and reputational headwinds in their largest market.
Telehealth platforms that have scaled through low-friction psychiatric prescribing may face new informed-consent documentation requirements.

Who is affected:

An estimated 46 million Americans currently taking at least one psychiatric medication.
VA patients, who would be directly affected by the Written Informed Consent Act if passed.
Primary care physicians, who prescribe the majority of antidepressants in the U. S.
Pharmacists, who field patient questions about discontinuation and side effects.

Who is not affected:

Patients on stable, long-term regimens with no side effects and no desire to discontinue. The policy does not require discontinuation; it requires informed consent and exit planning.

Cross-Layer Implications

Legal and regulatory: The New Mexico attorney general's ongoing bench trial against Meta — with a computer science expert testifying that the company should revise minor users' recommendation algorithms to prioritise safety over engagement — shows parallel regulatory pressure on algorithmic harms to mental health. The same week that HHS targets pharmacological interventions, courts are scrutinising digital ones.

Pharmaceutical regulatory: The MHRA's finasteride/dutasteride warning expansion on May 11 may trigger FDA review of the same products in the U. S. The updated UK warnings include persistent sexual dysfunction and suicidal ideation after cessation — conditions that have been reported in patient forums and litigation for years but under-recognised in formal labels.

Venture and market: If federal policy shifts even modestly toward non-pharmacological first-line mental health treatment, demand for psychotherapy, digital therapeutics with clinical validation, and neurostimulation devices may rise. The policy risk for psychiatric drug manufacturers is not prohibition but friction: longer consent processes, mandatory tapering discussions, and payer scrutiny.

Global health: Transatlantic regulatory coordination on psychiatric drug safety has historically been weak. The simultaneous UK warning expansion and U. S. policy shift in the same week suggests convergence may be accelerating — driven by patient-advocacy litigation, social-media amplified side-effect reporting, and post-COVID mental health demand that has strained both systems.

What This Means for You

For patients currently taking psychiatric medications:
Do not stop medications abruptly. SSRI and SNRI discontinuation syndromes can include dizziness, insomnia, irritability, and electric-shock sensations that may last weeks. If you are considering discontinuation, ask your prescriber for a tapering schedule before you need it. If your prescriber is unwilling to discuss tapering, seek a second opinion from a psychiatrist with explicit deprescribing experience — not a forum or an influencer.

For patients considering starting psychiatric medications:
Request written information about the specific drug, its side-effect profile, the expected duration of treatment based on your diagnosis, and the discontinuation protocol. This is now the standard the federal government is promoting, even if not yet enforcing. If your provider cannot supply this, ask why.

For prescribers (primary care and psychiatry):
Document informed consent conversations in the chart — not as a checkbox, but as a narrative. Expect CMS quality metrics and Medicare Advantage prior-authorisation requirements to incorporate medication-review frequencies and patient-education documentation. If you do not have a standardised tapering protocol for the antidepressants and antipsychotics you prescribe most often, develop one now.

For pharmacists:
Prepare for increased patient counselling on discontinuation schedules. The gap between prescriber knowledge and patient understanding of tapering is large, and pharmacists are often the most accessible clinicians. Stock or bookmark the Maudsley Deprescribing Guidelines and the NIH Deprescribing Research Network patient handouts.

For employers and health plan administrators:
Review mental health benefit designs. If federal policy increases the friction of medication-first treatment, demand for psychotherapy, psychiatric consultation, and evidence-based digital therapeutics will rise. Ensure your network capacity and utilisation management rules can absorb the shift without creating access barriers.

Uncertainty Ledger

No finalized CMS rules. The HHS and FDA announcements in May 2026 have not yet been codified as enforceable regulation. The Washington Post has documented a pattern of announcement-first, rulemaking-second under the current FDA leadership.
Clinical evidence gaps. Optimal deprescribing protocols — tapering rates, substitution strategies, relapse prevention — are well-studied for some drug classes (benzodiazepines, antipsychotics in schizophrenia) and thin for others (long-term SSRI maintenance, polypharmacy in bipolar disorder).
VA bill passage uncertain. The Written Informed Consent Act is pending in both House and Senate Veterans' Affairs Committees. No vote has been scheduled.
Provider workforce insufficient. If federal policy successfully reduces prescribing rates without expanding psychotherapy and psychiatric consultation capacity, the net effect may be untreated depression and anxiety — the outcome the APA warns against.
Unverified claim note: A May 4 "Dear Colleague" letter signed by four HHS divisions (CMS, SAMHSA, HRSA, ACF) urging providers to deliver risk/benefit information at initiation, during treatment, and at discontinuation was cited in a May 12 press release by CCHR International. We could not independently verify this letter on HHS.gov, CMS.gov, or SAMHSA.gov as of publication.

Bottom Line

The federal government is telling patients and providers that psychiatric medications are no longer a frictionless default. Informed consent, periodic re-evaluation, and safe tapering are becoming the new expectation — even where they are not yet the new rule. Whether this produces better patient outcomes or merely creates administrative friction depends on whether HHS funds the training, tapering protocols, and alternative therapies the policy shift implies, rather than just the announcements.

Sources

NPR, "RFK Jr.'s plan for antidepressants gets mixed reaction from psychiatrists," May 7, 2026 (Tier 1)
Iowa Public Radio / NPR, "Psychiatrists say RFK Jr.'s take on SSRIs is an 'oversimplification,'" May 7, 2026 (Tier 2)
NBC News, Nightly News netcast, "RFK Jr. launches plan to limit antidepressant prescriptions," May 5, 2026 (Tier 1)
CBS News Los Angeles, "Doctor discusses debate over psychiatric medications," May 8, 2026 (Tier 1)
The Guardian, "Trump's sudden cut in substance testing is 'going to kill people', experts warn," May 12, 2026 (Tier 1)
Newsweek, "Renewed Push in Veteran Bill That Would Change Medication Information," May 6, 2026 (Tier 2)
The Pharmaceutical Journal, "Psychiatric and sexual dysfunction warnings strengthened for finasteride and dutasteride," May 12, 2026 (Tier 2)
The Washington Post, "FDA's new playbook: Lots of media announcements but not much rulemaking," May 7, 2026 (Tier 1)